Navigation Links
LSUHSC research identifies new therapeutic target for Alzheimer's disease
Date:11/1/2012

New Orleans, LA Research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, has identified an enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target to treat or prevent Alzheimer's disease. The study was published online November 1, 2012 in the Online Now section of the journal Cell Reports.

The research team found that inactivation of MAGL, best known for its role in degrading a cannabinoid produced in the brain, reduced the production and accumulation of beta amyloid plaques, a pathological hallmark of Alzheimer's disease. Inhibition of this enzyme also decreased neuroinflammation and neurodegeneration, and improved plasticity of the brain, learning and memory.

"Our results suggest that MAGL contributes to the cause and development of Alzheimer's disease and that blocking MAGL represents a promising therapeutic target," notes Dr. Chu Chen, who is also a member of the Department of Otolaryngology at LSU Health Sciences Center New Orleans.

The researchers blocked MAGL with a highly selective and potent inhibitor in mice using different dosing regimens and found that inactivation of MAGL for eight weeks was sufficient to decrease production and deposition of beta amyloid plaques and the function of a gene involved in making beta amyloid toxic to brain cells. They also measured indicators of neuroinflammation and neurodegeneration and found them suppressed when MAGL was inhibited. The team discovered that not only did the integrity of the structure and function of synapses associated with cognition remain intact in treated mice, but MAGL inactivation appeared to promote spatial learning and memory, measured with behavioral testing.

Alzheimer's disease is a neurodegenerative disorder characterized by accumulation and deposition of amyloid plaques and neurofibrillary tangles, neuroinflammation, synaptic dysfunction, progressive deterioration of cognitive function and loss of memory in association with widespread nerve cell death. The most common cause of dementia among older people, more than 5.4 million people in the United States and 36 million people worldwide suffer with Alzheimer's disease in its various stages. Unfortunately, the few drugs that are currently approved by the Food and Drug Administration have demonstrated only modest effects in modifying the clinical symptoms for relatively short periods, and none has shown a clear effect on disease progression or prevention.

"There is a great public health need to discover new therapies to prevent and treat this devastating disorder," Dr. Chen concludes. The research was supported by grants from the National Institutes of Health. In addition to scientists from LSU Health Sciences Center New Orleans, the research team also included investigators from the Massachusetts Institute of Technology.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS
2. LSUHSC research finds treating stress prevented new MS brain lesions
3. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
4. Baylor University scientist receives major grants for health research on 1991 Gulf War veterans
5. Researchers use blood testing to predict level of enzymes that facilitate disease progression
6. Career Planning for Research Bioscientists
7. WSU researcher to study ecology of antibiotic resistance
8. NCH partners with Silicon Valley to market high-end diagnostic and medical research software
9. Researchers identify genetic basis of cardiac, craniofacial birth defects
10. Duke researchers engineer cartilage from pluripotent stem cells
11. Research provides new insights into dogs natural feeding behavior and finds they target a daily dietary intake that is high in fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):
(Date:5/6/2016)... ... May 06, 2016 , ... Crucial Life Sciences ... Version 4.1, greatly improves performance of the platform. In particular, Version 4.1 boosts ... volumes of data to be collected on a per patient basis. Clinical Studio ...
(Date:5/5/2016)... ... May 05, 2016 , ... Proove ... acquire Algynomics, a research-stage pain diagnostics company. The Algynomics platform and ... risk for the development of chronic pain, which will allow targeted preventive efforts, ...
(Date:5/5/2016)... Pa. , May 5, 2016  Why are ... and Lorna Weir launching a new ... way? Because they believe that truly helping clients raise ... of healthcare now demands a different type of collaboration. ... lab serving the pharmaceutical, biotechnology and medical device sectors. ...
(Date:5/4/2016)... ... May 05, 2016 , ... CereScan, the nation’s ... Stroke Association during National Stroke Awareness Month in May. An infographic created ... the month. CereScan will donate $1 up to a maximum of $3,000 ...
Breaking Biology Technology: